News Release

Latest News

November 7, 2024: Presentation document for Fiscal 2024 1st half (interim period) financial results
November 7, 2024: Consolidated Financial Results for the Six Months Ended September 30, 2024) [Japanese GAAP]
November 7, 2024: Consolidated Financial Results for Second Quarter (Interim Period) of FY2024 - Supplementary Information
November 7, 2024: Notice Regarding difference between financial forecast and actual results
August 2, 2024: Option Agreement for drug discovery of extracellular vesicles derived from airway epithelial cells
July 31, 2024: Summary of Consolidated Financial Results(For the first quarter ended June 30, 2024) [Japanese GAAP]
July 31, 2024: 1Q Consolidated Financial Results for the Fiscal Year Ending March 31, 2025 (September 31, 2024) - Supplementary Information
May 21, 2024: Notice of Dividends of Retained Earnings
May 10, 2024: Summary of Consolidated Financial Results(For fiscal year ended March 31, 2024) [Japanese GAAP]
May 10, 2024: Consolidated Financial Results for the Fiscal Year Ended March 31, 2024 (May 10 2024) - Supplementary Information
April 15, 2024: Starting Date of Operation at the New Head Office
February 6, 2024: Summary of Consolidated Financial Results(For third quarter ended December 31, 2023) [Japanese GAAP]
February 6, 2024: Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2024 (Feb 6, 2024) - Supplementary Information
January 22, 2024: Kyorin and Veneno conclude Joint Research Agreement for Functional DRPs
December 8, 2023: Imidafenacin for Overactive Bladder Launched in Mexico
November 8, 2023: Summary of Consolidated Financial Results(For second quarter ended September 30, 2023) [Japanese GAAP]
November 8, 2023: Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2024 (Nov 8, 2022) - Supplementary Information
November 8, 2023: Notice of differences between Forecasts and Actual Results
September 29, 2023: Notice Regarding Implementation of voluntary Retirement Program
August 2, 2023: Summary of Consolidated Financial Results(For the first quarter ended June 30, 2023) [Japanese GAAP]
August 2, 2023: 1Q Consolidated Financial Results for the Fiscal Year Ending March 31, 2024 (August 02, 2023) - Supplementary Information
May 22, 2023: Notice of Dividends of Retained Earnings
May 11, 2023: Summary of Consolidated Financial Results(For fiscal year ended May 11, 2023) [Japanese GAAP]
May 11, 2023: Consolidated Financial Results for the Fiscal Year Ended March 31, 2023 (May 11, 2023) - Supplementary Information
May 11, 2023: Kyorin Announces New Long-Term Vision "Vision 110" and Medium-Term Business Plan "Vision 110 -Stage 1-"
May 11, 2023: Notice of Relocation of Head Office
May 11, 2023: Notice of Extraordinary Income as Result of Absorption-Type Merger
April 27, 2023: KYORIN website has been relaunched today.
April 3, 2023: Notice of Absorption Type Merger of Wholly Owned Subsidiary KYORIN Pharmaceutical Co., Ltd and Change of Trade Name
March 6, 2023: KYORIN and Sumitomo Pharma Enter into License Agreement of Vibegron in Taiwan and Other Asian Countries
February 6, 2023: Summary of Consolidated Financial Results(For the third quarter ended December 31, 2022) [Japanese GAAP]
February 6, 2023: Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Feb 6, 2023) - Supplementary Information
November 9, 2022: KYORIN and SUSMED conclude Collaboration Research and Sales Agreement for development of DTx in Otolaryngology Field
November 9, 2022: Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Nov 9, 2022) - Supplementary Information
November 9, 2022: Summary of Consolidated Financial Results(For the second quarter ended September 30, 2022) [Japanese Standard]
August 2, 2022: Notice Regarding Decision on Termination and Dissolution of Business in Consolidated Subsidiaries, ActivX Biosciences, Inc.
August 2, 2022: First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Aug 2, 2022) - Supplementary Information
August 2, 2022: Summary of Consolidated Financial Results(For the first quarter ended June 30, 2022) [Japanese Standard]
June 17, 2022: KYORIN Signs Joint Development and License Agreement for Genetically modified Adipocyte, Treatment Agent for Fabry Disease
May 17, 2022: Notice of Resumption of Operation at Nishinihon Delivery Center
May 11, 2022: Notice of Reduction of Capital Reserve
May 11, 2022: Absorption Type Merger (Simplified Merger and Short-Form Merger) of Wholly Owned Subsidiary　KYORIN Pharmaceutical Co., Ltd., Change of Trade Name and Partial Amendment to Articles of Incorporation
May 11, 2022: Consolidated Financial Results for the Fiscal Year Ended March 31, 2022 (May 11, 2022) - Supplementary Information
May 11, 2022: Summary of Consolidated Financial Results(For the fiscal year ended March 31, 2022) [Japanese Standard]
April 26, 2022: Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2022
April 20, 2022: NHI Drug Price Listing and Release of a selective P2X3 receptor antagonist for the treatment of cough "Lyfnua® Tablet 45 mg"
March 30, 2022: KYORIN and Lumen Bioscience Reach Collaboration Research Agreement
March 17, 2022: KYORIN and Nanjing Neiwa Faith Signed License Agreement for Lascufloxacin in China
February 24, 2022: Construction of the Takaoka New Plant by a Subsidiary Company
February 4, 2022: Summary of Consolidated Financial Results (For the Third Quarter Ended December 31, 2021) [Japanese Standard]